CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence
Authors
Keywords
-
Journal
MODERN PATHOLOGY
Volume 30, Issue 7, Pages 1032-1041
Publisher
Springer Nature
Online
2017-03-10
DOI
10.1038/modpathol.2017.15
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: A National Cancer Data Base study
- (2016) Nicholas R. Rydzewski et al. CANCER
- Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts
- (2016) Ellen Stelloo et al. CLINICAL CANCER RESEARCH
- Identification of microRNA expression profile related to lymph node status in women with early-stage grade 1–2 endometrial cancer
- (2016) Geoffroy Canlorbe et al. MODERN PATHOLOGY
- A clinically applicable molecular-based classification for endometrial cancers
- (2015) A Talhouk et al. BRITISH JOURNAL OF CANCER
- Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors
- (2015) K. Chen et al. CLINICAL CHEMISTRY
- A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
- (2015) Funda Meric-Bernstam et al. JNCI-Journal of the National Cancer Institute
- Small non-coding RNA deregulation in endometrial carcinogenesis
- (2015) Maria Ravo et al. Oncotarget
- A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
- (2015) Funda Meric-Bernstam et al. JNCI-Journal of the National Cancer Institute
- β-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers
- (2014) Andrea Myers et al. GYNECOLOGIC ONCOLOGY
- Clinical Significance of CTNNB1 Mutation and Wnt Pathway Activation in Endometrioid Endometrial Carcinoma
- (2014) Yuexin Liu et al. JNCI-Journal of the National Cancer Institute
- Alterations in Wnt-β-catenin and Pten signalling play distinct roles in endometrial cancer initiation and progression
- (2013) Marten van der Zee et al. JOURNAL OF PATHOLOGY
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K–AKT, Wnt/β-catenin and P53 pathway activation
- (2012) Remi A. Nout et al. GYNECOLOGIC ONCOLOGY
- Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility
- (2012) O Aprelikova et al. ONCOGENE
- FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
- (2012) Sara A. Byron et al. PLoS One
- Fifteen-Year Radiotherapy Outcomes of the Randomized PORTEC-1 Trial for Endometrial Carcinoma
- (2011) Carien L. Creutzberg et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Specific Mutations in the β-Catenin Gene (CTNNB1) Correlate with Local Recurrence in Sporadic Desmoid Tumors
- (2008) Alexander J.F. Lazar et al. AMERICAN JOURNAL OF PATHOLOGY
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
- (2008) Paul A. Harris et al. JOURNAL OF BIOMEDICAL INFORMATICS
- β-catenin mediates glandular formation and dysregulation of β-catenin induces hyperplasia formation in the murine uterus
- (2008) J-W Jeong et al. ONCOGENE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started